These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35156191)

  • 1. Voxelotor and albuminuria in adults with sickle cell anaemia.
    Han J; Molokie RE; Hussain F; Njoku F; Gordeuk VR; Saraf SL
    Br J Haematol; 2022 Jun; 197(5):e63-e64. PubMed ID: 35156191
    [No Abstract]   [Full Text] [Related]  

  • 2. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
    Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials.
    Tanriverdi LH; Sarici A; Erkurt MA; Parlakpinar H
    Int J Clin Pract; 2021 Jun; 75(6):e13967. PubMed ID: 33369007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voxelotor in sickle cell disease.
    Bain BJ; Myburgh J; Hann A; Layton DM
    Am J Hematol; 2022 Jun; 97(6):830-832. PubMed ID: 35349729
    [No Abstract]   [Full Text] [Related]  

  • 5. Voxelotor for the Treatment of Sickle Cell Disease.
    Fantasia HC; Morse BL
    Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voxelotor for the treatment of sickle cell disease in pediatric patients.
    Brown C; Tonda M; Abboud MR
    Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease.
    Nagalapuram V; Kanter J
    Am J Hematol; 2022 Aug; 97(8):E318-E320. PubMed ID: 35702869
    [No Abstract]   [Full Text] [Related]  

  • 8. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
    Ferlis M; Lipato T; Roseff SD; Smith WR
    Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxelotor for the treatment of sickle cell disease.
    Vissa M; Vichinsky E
    Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
    [No Abstract]   [Full Text] [Related]  

  • 11. Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.
    Ershler WB; Holbrook ME
    Transfusion; 2020 Dec; 60(12):3066-3067. PubMed ID: 32815179
    [No Abstract]   [Full Text] [Related]  

  • 12. Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
    Çanak B; Eşkazan AE
    Br J Clin Pharmacol; 2022 Jun; 88(6):2564-2565. PubMed ID: 35158414
    [No Abstract]   [Full Text] [Related]  

  • 13. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
    Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
    Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
    Chen M; Hankins JS; Zhang M; Ataga KI
    Am J Hematol; 2024 Feb; 99(2):E37-E41. PubMed ID: 37950855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voxelotor treatment of a patient with sickle cell disease and very severe anemia.
    Shet AS; Mendelsohn L; Harper J; Ostrowski D; Henry ER; Gwaabe E; Nichols J; Alayash AI; Eaton WA; Thein SL
    Am J Hematol; 2019 Apr; 94(4):E88-E90. PubMed ID: 30592074
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease.
    Minniti CP; Knight-Madden J; Tonda M; Gray S; Lehrer-Graiwer J; Biemond BJ
    Am J Hematol; 2021 Apr; 96(4):E126-E128. PubMed ID: 33476432
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of Voxelotor on quantitation of HbS levels by high-performance liquid chromatography in a patient with sickle cell disease.
    Giacomini L; Puricelli C; Sacchetti S; Zanotti V; Rolla R
    Int J Lab Hematol; 2023 Dec; 45(6):831-832. PubMed ID: 37604778
    [No Abstract]   [Full Text] [Related]  

  • 19. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
    Green ML; Savic RM; Tonda M; Jorga K; Washington CB
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxelotor use in adults with sickle cell disease in a real-world setting.
    Curtis SA; Betancourt J; Kottapalli N; Campbell S; Minniti C
    Am J Hematol; 2022 Mar; 97(3):E125-E128. PubMed ID: 34967959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.